Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 11, 2012, Pages 2360-2366

  Chillon M C ^a   Gomez Casares M T ^b   Lopez Jorge C E ^b   Rodriguez Medina, C ^b   Molines, A ^c   Sarasquete, M E ^a   Alcoceba, M ^a   Miguel, J D G S ^b   Bueno, C ^d   Montes, R ^d   Ramos, F ^e   Rodriguez J N ^f   Giraldo, P ^g   Ramirez M ^h   Garcia Delgado R ⁱ   Fuster, J L ^j   Gonzalez Diaz M ^a   Menendez, P ^d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^d JUNTA DE ANDALUCÍA   (Spain)

^e UNIVERSITY OF LEÓN   (Spain)

^f HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

ⁱ Hospital Clinico de Malaga   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

more..

Author keywords

B ALL; FLT3 expression; FLT3 mutations; Fusion genes; MLL AF4; T ALL

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; DISEASE FREE SURVIVAL; FTL 3 GENE; GENE; GENE DUPLICATION; GENE EXPRESSION PROFILING; GERM LINE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION;

FMS-LIKE TYROSINE KINASE 3; HUMANS; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 84869080524     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.161     Document Type: Article

References (34)

1. Bueno C, Montes R, Catalina P, Rodriguez R, Menendez P. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia 2011; 25: 400-410.
2. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid Deregulation and hematologic malignancy. Blood 2006; 108: 669-677. (Pubitemid 44061369)
3. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355-368.
4. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006; 25: 3093-3103. (Pubitemid 43881551)
5. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183. (Pubitemid 37443389)
6. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103: 3544-3546. (Pubitemid 38525690)
7. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 2005; 115: 919-929. (Pubitemid 40489396)
8. Yamaguchi H, Hanawa H, Uchida N, Inamai M, Sawaguchi K, Mitamura Y et al. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression. Exp Hematol 2009; 37: 701-714.
9. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542. (Pubitemid 34925124)
10. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918. (Pubitemid 27019637)
11. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, KoDera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439. (Pubitemid 32291491)
12. Emerenciano M, Menezes J, Vasquez ML, Zalcberg I, Thuler LC, Pombo-de-Oliveira MS. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. Leuk Lymphoma 2008; 49: 2291-2297.
13. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103: 1085-1088. (Pubitemid 38129575)
14. Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Brit J Haematol 1999; 105: 155-162. (Pubitemid 29197158)
15. Stam RW, den Boer ML, SchneiDer P, Meier M, Beverloo HB, Pieters R. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007; 92: 1565-1568. (Pubitemid 350144134)
16. Stam RW, SchneiDer P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2007; 110: 2774-2775. (Pubitemid 47523212)
17. Bardini M, Galbiati M, Lettieri A, Bungaro S, Gorletta TA, Biondi A et al. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia 2011; 25: 175-178.
18. Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I et al. DNA copynumber abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia 2010; 24: 169-176.
19. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixedlineage leukemia. Genes Dev 2008; 22: 3403-3408.
20. Menendez P, Vargas A, Bueno C, Barrena S, Almeida J, De Santiago M et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004; 18: 491-498. (Pubitemid 38425863)
21. Gabert J, Beillard E, Van Der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a europe against cancer program. Leukemia 2003; 17: 2318-2357. (Pubitemid 38072573)
22. Chillon MC, Santamaria C, Garcia-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M et al. Long FLT3 internal tandem duplications and reduced PMLRARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica 2010; 95: 745-751.
23. Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Ramos F et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009; 114: 148-152.
24. Menendez P, Perez-Simon JA, Mateos MV, Caballero MD, Gonzalez M, San-Miguel JF et al. Influence of the different CD34 and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. Br J Haematol 2002; 119: 135-143. (Pubitemid 35176513)
25. Menendez P, Caballero MD, Prosper F, Del Canizo MC, Perez-Simon JA, Mateos MV et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002; 42: 1159-1172.
26. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 2010; 115: 3570-3579.
27. Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Leuk Res 2010; 35: 305-309.
28. Bueno C, Catalina P, Melen GJ, Montes R, Sanchez L, Ligero G et al. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 2009; 30: 1628-1637.
29. Bueno C, Montes R, Martin L, Prat I, Hernandez MC, Orfao A et al. NG2 antigen is expressed in CD34 HPCs and plasmacytoid dendritic cell precursors: Is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia 2008; 22: 1475-1478.
30. Bueno C, Montes R, Melen GJ, Ramos-Mejia V, Real PJ, Ayllon V et al. A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res 2012; 22: 986-1002.
31. Menendez P, Bueno C, Wang L. Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy 2006; 8: 530-541. (Pubitemid 44869853)
32. Menendez P, Catalina P, Rodriguez R, Melen GJ, Bueno C, Arriero M et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4 acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009; 206: 3131-3141.
33. Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, Ponce L et al. Enforced expression of MLL-AF4 fusion in cord blood CD34 cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 2011; 117: 4746-4758.
34. Stam RW, SchneiDer P, Hagelstein JA, Van Der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835-2844.